Figure 1.

Summary of clinical trials and patients in the all-exposed population. aDoes not include patients from study 1; bExtension studies are ongoing; most patients receive 8 mg/kg TCZ + MTX/DMARDs; cAll patients who received TCZ treatment; from their first dose (either in a core or an extension study) up to a cutoff date of February 6, 2009. DMARD-IR, inadequate responder to disease-modifying antirheumatic drugs; MTX, methotrexate; study 1, clinical pharmacology study; study 2, AMBITION; study 3, RADIATE; study 4, TOWARD; study 5, OPTION, study 6, LITHE; TCZ, tocilizumab; TNF-IR, inadequate responder to tumor necrosis factor inhibitor.

Schiff et al. Arthritis Research & Therapy 2011 13:R141   doi:10.1186/ar3455
Download authors' original image